The Antibody and Recombinant Protein CDMO Market Size is valued at USD 16.2 billion in 2023 and is predicted to reach USD 36.1 billion by the year 2031 at a 10.8% CAGR during the forecast period for 2024-2031.
The antibody and recombinant protein CDMO (Contract Development and Manufacturing Organization) market is a subset of the biopharmaceutical industry that is focused on the development as well as production of recombinant proteins and antibodies. CDMOs provide comprehensive end-to-end services for biotechnology and pharmaceutical firms, encompassing everything from early-stage research, including cell line development and process optimization, to large-scale manufacturing, regulatory support, and final product commercialization. The market for antibody and recombinant protein CDMO is anticipated to develop significantly over the next several years due to a number of causes, including the rising incidence of chronic illnesses, the growing need for tailored therapy, and biotechnology advancements. The increasing practice of pharmaceutical companies outsourcing manufacturing services to CDMOs is driving the market as well.
Furthermore, several companies in the fiercely competitive antibody and recombinant protein CDMO industry provide a variety of services, such as cell line creation, antibody production, and recombinant protein expression. In order to get a competitive edge, market participants are also concentrating on growing the range of services they offer, making investments in research and development, and forming strategic alliances.
Competitive Landscape
Some Major Key Players In The Antibody and Recombinant Protein CDMO Market:
- Batavia Biosciences
- Grifols
- Biovian Oy
- Catalent
- Bioinnobio
- Thousand Oaks Biopharmaceuticals
- Goodwin Biotechnology
- Cerbios-Pharma SA
- HALIX
- Merck
- Hangzhou Hs-biopharm
- Wuxibiologics
- Cerbios-Pharma SA
- Genscriptprobio
- Vetter
- Etinpro (Beijing) Co
- Boehringer Ingelheim BioXcellence
- Eurogentec
- HJB
- Bibo Pharma
- MabPlex International
- Lonza
- 3SBio Inc
- Porton
- Other Market Players
Market Segmentation:
The antibody and recombinant protein CDMO market is segmented based on type and application. Based on type, the market is segmented into Antibody CDMO and Recombinant Protein CDMO. As per application segment, the market is segmented into Pharmaceutical Company, Biotechnology Company, and Generic Company.
Based On The Type, The Antibody CDMO Segment Accounts For A Major Contributor To The Antibody And Recombinant Protein CDMO Market.
The antibody CDMO category is expected to hold a major global market share in 2023, driven by the growing need for biological medicines, in particular monoclonal antibodies, which are being utilized more and more to treat infectious diseases, autoimmune disorders, and cancer, among other chronic illnesses. A unique set of skills that CDMOs may offer is efficient and scalable production, which is required in light of the increasing investments in biotechnology and the need for novel therapeutic solutions. Furthermore, the productivity and economy of antibody production are being improved by developments in bioprocessing technologies, such as continuous manufacturing and single-use systems.
Biotechnology Company Segment To Witness Growth At A Rapid Rate
The growth of biotechnology companies is propelled by the rising need for biologics, specifically recombinant proteins and monoclonal antibodies, which are crucial for creating novel treatments. Leading this surge are biotechnology companies, using cutting-edge technologies and specialized knowledge to address the intricate needs of producing biologics. Biotechnology businesses are key actors in the CDMO landscape as a result of the increased emphasis on customized treatment and the rise in chronic diseases, which drive up demand for these biologics.
In The Region, The North American Antibody And Recombinant Protein CDMO Market Holds A Significant Revenue Share.
The North American antibody and recombinant protein CDMO market is expected to note the highest market share in revenue in the near future. The main nations in North America that are propelling market expansion are the United States and Canada. Significant elements fostering market expansion in this area include the existence of significant biotechnology and pharmaceutical firms as well as an established healthcare system. There is a growing need for personalized medicine, and the area is experiencing a rise in investments in healthcare infrastructure. Additionally, the region's increasing emphasis on research and development initiatives is fueling the market's expansion. In addition, Asia Pacific is likely to grow rapidly in the global market. Some of the important drivers of market expansion in the Asia Pacific region include rising investments in the biotechnology and healthcare sectors as well as rising biologics demand.
Antibody and Recombinant Protein CDMO Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 16.2 Bn |
|
Revenue Forecast In 2031 |
USD 36.1 Bn |
|
Growth Rate CAGR |
CAGR of 10.8% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, And Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Batavia Biosciences, Grifols,Biovian Oy, Catalent, Bioinnobio, Thousand Oaks Biopharmaceuticals, Goodwin Biotechnology, Cerbios-Pharma SA, HALIX, Merck, Hangzhou Hs-biopharm, Wuxibiologics, Cerbios-Pharma SA, Genscriptprobio, Vetter, Etinpro (Beijing) Co, Boehringer Ingelheim BioXcellence, Eurogentec, HJB, Bibo Pharma, MabPlex International, Lonza, 3SBio Inc, and Porton. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
